SecBot SecBot
SECBOTREPLAY Home › Report › RGNX

RGNX · REGENXBIO reported financial results for Q4 and full year 2025, showing…

REGENXBIO Inc. · 8-K filed Mar 5, 2026 at 07:31 ET

At the news

MIXEDIMPACT 6/10

8-K filed Mar 5, 2026 at 07:31 ET

REGENXBIO reported financial results for Q4 and full year 2025, showing increased revenue driven by collaboration income and royalty growth, while net loss narrowed year-over-year. The company highlighted clinical progress in its gene therapy pipeline, including upcoming data readouts for RGX-202 in Duchenne muscular dystrophy and sura-vec in wet AMD, but also disclosed ongoing regulatory challenges with RGX-121 following a clinical hold and CRL from the FDA.

  • Revenue increased to $170.4M for FY2025 (from $83.3M in FY2024), driven by $72.9M in upfront license revenue from Nippon Shinyaku partnership and higher Zolgensma/Itvisma royalties
  • Net loss narrowed to $193.9M for FY2025 (from $227.1M in FY2024) despite higher R&D and G&A expenses
  • Cash position was $240.9M as of December 31, 2025, expected to fund operations into early 2027
  • RGX-121 received a Complete Response Letter from FDA and remains on clinical hold, creating regulatory uncertainty

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access